Following the identification that the function of CTLA-4 and B7 is to suppress T-cell activation, it was shown in 1996 that anti-CTLA-4 antibodies could clear carcinomas and fibrosarcomas from mice, which provided the first in vivo evidence of efficacy for a checkpoint inhibitor as an anti-cancer therapy [278]. This evidence concerns the gene CTLA4 and carcinoma.